GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
GSK Pharmaceuticals has published its audited financial results for Q4 and full year ended March 31, 2026 in newspapers (Economic Times, Business Standard, Maharashtra Times) as per SEBI LODR requirements. Consolidated revenue for FY26 stood at ₹3,79,020 lakhs, up 1.8% from ₹3,72,349 lakhs in FY25. Net profit after tax grew 10.1% to ₹1,01,182 lakhs from ₹91,906 lakhs. For Q4 FY26 alone, revenue was ₹96,915 lakhs and net profit was ₹27,404 lakhs. Standalone revenue for FY26 was ₹3,82,167 lakhs with net profit of ₹1,03,598 lakhs, up 11.7% YoY. EPS (diluted, after exceptional items) improved to ₹61.15 on standalone basis versus ₹54.76 in the previous year.
The company demonstrated solid profitability growth with net profit rising over 10% YoY despite modest revenue growth, indicating improved operational efficiency. Strong EPS growth is positive for shareholders and suggests better cost management.